Sugi Predict

Sugi Predict / Targets / CXCL10

CXCL10

C-X-C motif chemokine 10 · P02778 · CXCL10 on Sugi Atlas →

243 patent compounds predicted against CXCL10, 178 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL18118449 SCHEMBL18118449 0.56 1/20
SCHEMBL30013150 SCHEMBL30013150 0.56 1/20
SCHEMBL12799309 SCHEMBL12799309 0.55 1/20
SCHEMBL10085262 SCHEMBL10085262 0.51 1/20
SCHEMBL15942927 SCHEMBL15942927 0.51 1/20
SCHEMBL17167539 SCHEMBL17167539 0.50 1/20
SCHEMBL19980809 SCHEMBL19980809 0.50 1/20
SCHEMBL17167857 SCHEMBL17167857 0.49 1/20
SCHEMBL18122114 SCHEMBL18122114 0.49 1/20
SCHEMBL17879093 SCHEMBL17879093 0.48 1/20
SCHEMBL12458594 SCHEMBL12458594 0.48 1/20
SCHEMBL9217731 SCHEMBL9217731 0.47 1/20
SCHEMBL12360709 SCHEMBL12360709 0.47 1/20
SCHEMBL17521900 SCHEMBL17521900 0.47 1/20
SCHEMBL17636496 SCHEMBL17636496 0.47 1/20
SCHEMBL17636503 SCHEMBL17636503 0.47 1/20
SCHEMBL17636504 SCHEMBL17636504 0.47 1/20
SCHEMBL17643051 SCHEMBL17643051 0.47 1/20
SCHEMBL19271998 SCHEMBL19271998 0.47 1/20
SCHEMBL19272020 SCHEMBL19272020 0.47 1/20

Clinical trials — most relevant to CXCL10 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant PHASE4COMPLETED
Vitiligo, New Treatment and Serum s100B PHASE2/PHASE3RECRUITING
Efficacy of Ibuprofen Chronotherapy in Healing After Surgical Extraction of the Mandibular Third Molar PHASE2/PHASE3UNKNOWN
P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19 PHASE2/PHASE3UNKNOWN
Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer PHASE2NOT_YET_RECRUITING
Dose-Ranging Study to Assess the Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19 PHASE2WITHDRAWN
SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer. PHASE2NOT_YET_RECRUITING
Tocilizumab Treatment in Patients With COVID-19 PHASE2ACTIVE_NOT_RECRUITING
A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis PHASE1COMPLETED
Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA nanRECRUITING
Ankylosing Spondylitis nanNOT_YET_RECRUITING
Value of Various Chemokines in the Detection and Follow up of RCC nanUNKNOWN
Measuring the Healthy Pediatric Inflammatory Response to Vaccination. nanENROLLING_BY_INVITATION
Characterization of Microbiological and Genetic Features in Prostate Cancer and Their Association with Disease Stage nanENROLLING_BY_INVITATION
Early Regenerative Intervention for Post-Traumatic Osteoarthritis nanUNKNOWN
Gingival Crevicular Fluid Biomarkers and Healing After Root Canal Treatment in Asymptomatic Apical Periodontitis nanACTIVE_NOT_RECRUITING
Tregs CD25 CXCL9 in Vitiligo nanUNKNOWN
Detection of Circulating Biomarkers of Immunogenic Cell Death nanCOMPLETED
Monocytes and NK Cells Activity in Covid-19 Patients nanUNKNOWN
Replacement of Vitamin D in Patients With Active Tuberculosis nanCOMPLETED
The Role of MMPs in the CXCL12-Induced Invasion of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma nanUNKNOWN
Lung Immune Challenge Study: Controlled Exposure to Inhaled Resiquimod (R848) nanRECRUITING
Evaluation of IFNγ and Inflammatory Mediators in Patients With Hemophagocytic Lymphohistiocytosis nanCOMPLETED
The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma nanUNKNOWN
The Role of Granulation Tissue in Periodontal Regeneration nanRECRUITING
Immunology Dysregulation in Lymphadenitis Tuberculosis : An Observational Study Using Patient' Block Paraffins 2019 Until 2021 nanCOMPLETED
Circular RNA and Chemerin in Breast Cancer Patient nanUNKNOWN
PROACT Pilot Trial nanACTIVE_NOT_RECRUITING
The Role of Stromal Cell-Derived Factor-1 (SDF-1)/CXC Chemokine Receptor 4 (CXCR4) in Metastasis of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma nanUNKNOWN
Head and Neck Advanced Research for Multi-Omics and Optimized Immunotherapy nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a CXCL10 binder may also engage these)

ProteinNameSimilarity
Q8MIZ1 — 1.000 Q8MIZ1 →
Q865F5 — 1.000 Q865F5 →
Q2KIQ8 — 1.000 Q2KIQ8 →
P17515 — 1.000 P17515 →
Q5KSV9 — 0.997 Q5KSV9 →
Q102R3 — 0.994 Q102R3 →
P48973 — 0.993 P48973 →
P49113 — 0.993 P49113 →
P22362 — 0.992 P22362 →
A0A0R4INB9 — 0.991 A0A0R4INB9 →
O55038 — 0.991 O55038 →
O43927 — 0.990 O43927 →
Q7YRB5 — 0.989 Q7YRB5 →
B0R191 — 0.989 B0R191 →
P41324 — 0.988 P41324 →
A9QWP9 — 0.988 A9QWP9 →
P26894 — 0.987 P26894 →
Q9XSX5 — 0.987 Q9XSX5 →
P10146 — 0.982 P10146 →
P36925 — 0.982 P36925 →
P18340 — 0.982 P18340 →
P10720 — 0.982 P10720 →
O62812 — 0.981 O62812 →
Q09141 — 0.981 Q09141 →
P06765 — 0.981 P06765 →
CXCL8 Interleukin-8 0.981 landscape →
P48298 — 0.981 P48298 →
P82943 — 0.981 P82943 →
P19874 — 0.980 P19874 →
O70460 — 0.980 O70460 →